relative bioavailability

Sometimes you cannot or need not compare a product against an intravenous shot — you just want to know how it stacks up against another oral product. Relative bioavailability answers that: it compares the amount of drug reaching the circulation from a test formulation with the amount from a reference formulation given by the same or another non-IV route. It is bioavailability measured against a peer, not against the gold standard.

It is computed as a ratio of dose-corrected exposures: F_rel = (AUC_test / Dose_test) ÷ (AUC_reference / Dose_reference). A value near 1 (100%) means the two products deliver similar amounts; a value above or below shows one outperforms the other. Because both products travel the same imperfect route, relative bioavailability does not reveal the absolute fraction reaching the blood — only the comparison.

This is the everyday measure for development questions: a new tablet versus an old capsule, a suspension versus a solution, with food versus fasting, or a generic versus the brand. When a relative-bioavailability comparison meets statistical equivalence criteria for both rate and extent, it becomes a bioequivalence study — the legal basis for approving generic products.